

## Diabetic Retinopathy Guideline Committee Meeting 12

**Date:** 20<sup>th</sup> April 2023  
**Location:** Virtual Meeting via Zoom  
**Minutes:** Final

<b>Committee members present:</b>	
Mike Burdon (Chair)	Present for all items
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Rosalind Creer	Present for all items
Julie Davey	Present for all items
Christiana Dinah	Present for all items
Noemi Lois	Present for all items
Diva Shah	Present for all items
Lloyd Thomas	Present for all items
Bernadette Warren	Present for all items
Becky Wei Luo	Present for all items

<b>In attendance:</b>		
Astrid Aregui (AA)	Senior Medical Editor, NICE	Present for all items
Keona Bennett	Administrator, Guideline Development Team	Present for item 1
Catrina Charlton	Guideline Commissioning Manager, NICE	Present for all items
Clare Dadswell (CD)	Senior Technical Analyst	Present for all items
Jon Littler (JL)	Project Manager, Guideline Development Team	Present for all items
Kirsty Luckham (KL)	Technical Analyst (Health Economics)	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Philip Williams	NICE Resource Impact Lead	Present for all items
Ahmed Yosef (AY)	Technical Analyst, Guideline Development Team	Present for all items

<b>Apologies:</b>	
John Anderson	Committee Member
Louis Savage	Committee Member

## **1. Welcome and DOIs for the meeting**

The Chair welcomed the committee members and attendees to the 12th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared.

## **2 – 4. Recapping the recommendations on the full guideline.**

The Chair, Mike Burdon (MB) introduced Clare Dadswell (CD), Senior Technical Analyst, and Astrid Aregui (AA), Medical Editor. CD, along with the support of AA, then took the next 3 agenda sessions to guide the committee through all the recommendations drafted (and re-drafted) so far in the development of this guideline, with the goal of adding to and improving these recommendations for the upcoming consultation.

After an in-depth discussion on the recommendations, with changes and refinements made, CD thanked the committee for their work in getting them ready for stakeholders to review at consultation before the Chair moved the meeting on to the next item on the agenda.

## **5. Equality considerations**

The Chair reintroduced CD who began to take the committee through the updated health inequalities assessment for this guideline. CD asked them for any input they had to improve upon the considerations that the NICE team had already added to this document.

CD made changes and additions in line with committee discussion, before the Chair thanked her and the committee for their work and moved to the final item on the agenda.

## **6. AOB, summary and next steps**

The Chair thanked the committee and the NICE team for the hard work they had put in on development so far. He then introduced Jon Littler (JL), Project Manager, who advised the committee of the next steps of the guideline.

JL advised them that the consultation for the Diabetic Retinopathy update was expected to begin on 27 July 2023 and conclude on 7 September 2023. He also advised them that there would be a further committee meeting held in late September 2023 (date TBC) to discuss stakeholder comments and to refine the guideline for publication.

The Chair then concluded the meeting.